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INTRODUCTION 
Over the past decades, excipient suppliers have developed 
novel mixtures and new physical forms of excipients that 
are tailored to the needs of newer delivery platforms 
(transdermal, pulmonary, oral modified release). Most 
excipient manufacturers however concentrate on 
modifying existing excipients as opposed to developing 
entirely new ones. This is so because regulatory 
restrictions have made innovation rather difficult. Under 
US law, an excipient cannot be sold for use in approved 
drugs unless it can be qualified through one or more of the 
three FDA approval mechanisms.These include 
determination by FDA that the substance is "generally 
recognized as safe" (GRAS), is approved through a food 
additive petition, or is referenced in an approved new drug 
application (NDA) for a particular function in that specific 
drug product.  
The International Pharmaceutical Excipients Council 
(IPEC) spells out 13 general categories of excipients for 
solid dosage forms based on function: binders, 
disintegrants, fillers, lubricants, glidants, compression aids, 
colors, sweeteners, preservatives, suspending /dispersing 
agents, film formers/coatings, flavors, and printing inks. 
This Update paper cites a few examples, where novel 
excipients or existing excipients in novel roles caused a 
significant improvement in product performance. 
EXCIPIENT SYNERGIES AND 
MULTIFUNCTIONALITY: 
Improving Flowability 
Today, it is not unheard of to have tableting equipment 
compressing 8,000 to 10,000 tablets per minute. It is 
critical under these conditions to have an excellent flowing 
granulation/powder blend. Many sugar-based excipients, 
such as maltose, mannitol, and sorbitol are not 
compressible in their natural state and need to be modified 
for use in direct compression tableting. 
AdvantoseTM 100 maltose powder (SPI Polyols) is a 
disaccharide carbohydrate, with flow and tableting 
properties that are greatly improved by the process of 
spray drying. Spray-dried AdvantoseTM 100 particles are 
spherical with an optimal combination of fine and coarse 
particles that contributes to superior flow. When compared 
to microcrystalline cellulose (MCC), spray-dried maltose 
can tolerate significantly greater compression forces 
(>4000 lb) without capping 
upon ejection from the tableting die. It also exhibits lower 
hygroscopicity and lower reactivity; thus providing more 
stable tablets as compared to those made with MCC. 
Formulating a High-Dose Active Formulation 
Formulations prepared using a high concentration of active 
or multiple actives pose challenges, such as segregation of 
powder blends, low content uniformity, and poor flow. 
Such formulations require excessive amounts of 
conventional binders, such as MCC and dicalcium 
phosphate (DCP) to achieve workable compactibility. 
Maintaining tablet size then becomes an additional cause 
of concern. 
ProSolv SMCCTM (Penwest Pharmaceuticals) is a patented 
combination of MCC and colloidal silicon dioxide (CSD), 
known to work together synergistically to optimize product 
performance. Formulating with ProSolv SMCCTM has been 
shown to reduce binder usage by more than half, cutting 
tablet size consequently. Hence, it is ideally suited to high-
dose direct-compression formulations in which it has 
advantages in both flow and compactibility over 
conventional MCC.  
Dealing with difficult actives 
Many new drug candidates exhibit poor solubility and 
stability. Excipient compatibility is another issue with 
some of these compounds. Furthermore, some 
macromolecular peptide and protein drugs need to be 
protected and delivered safely through the gastrointestinal 
tract to the site of most active absorption. 
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Formulating a Moisture-Sensitive Active 
Corn starch has long been used as disintegrate in oral solid 
dosage forms. Physical modifications of corn starch, 
through partial pregelatinization (Starch 1500TM, 
Colorcon) have added functional benefits in terms of 
flowability and lubricity, while retaining its disintegrant 
capability and moisture stability. 
Superdisintegrants function primarily by drawing large 
amounts of water into the tablet while simultaneously 
swelling. It is this great affinity for water that can impact 
the stability of moisture-sensitive materials under 
accelerated storage conditions. Partially pregelatinized 
starchhas been shown to exhibit a lower propensity for 
moisture, thus providing excellent stabilization of 
formulations. 
Formulating a Poorly Soluble Active 
Almost 10% of currently marketed drugs are poorly 
soluble. Almost 40% of new chemical entities (NCE) are 
dropped due to solubility issues. Poor water solubility 
leads to poor dissolution kinetics and suboptimal 
bioavailability. NanoCrystal® (Elan Pharmaceuticals) and 
NanoEdge® (Baxter Healthcare) technologies involve 
decreasing the particle size of actives to nanometer size 
range, thus leading to an increase in the surface area and a 
subsequent increase in dissolution rate. These drug 
particles are stabilized against agglomeration by surface 
adsorption of selected proprietary GRAS excipients, such 
as ionic surfactants and block copolymers. The result is a 
colloidal dispersion, which can later be freeze dried or 
spray dried to yield nanoparticles in the 500-nm range. 
This is an attractive option for actives with high toxicity 
and low potency. 
Formulating a Poorly Absorbed Active 
Another major hurdle to effective oral drug delivery in 
humans is poor absorption of drugs through the epithelial 
membrane. Biopharmaceutical studies have shown that 
vitamin E TPGSTM (a-tocopheryl PEG 1000 succinate, 
Eastman Chemical Company) can be used as a safe and 
effective absorption enhancer for poorly absorbed drugs, 
such as cyclosporine and protease inhibitors. It functions 
so by enhancing the solubility and permeability of drugs. 
Working Around Drug-Excipient Incompatibility 
Excipients can interact with drugs in the solid state by: 
acting as a moisture source, providing surface contact 
points, lowering the drug melting point by forming a 
eutectic mixture, and acting as a reaction catalyst or 
chemical reactant. DI-TABTM (dicalcium phosphate, 
Rhodia) is a directly compressible filler-binder that 
contains "mobile" water of crystallization. These water 
molecules can be transferred to other components in the 
formulation during tableting or aging. Rhodia has taken 
this established product and developed a product called A-
TAB
TM
, anhydrousdicalcium phosphate. A-TAB
TM
 is very 
stable at high temperatures and humidities, thus stabilizing 
the formulation. 
One of the more common drug-excipient incompatibilities 
is the reaction between aldehydic sugars, such as lactose 
and primary and secondary amines, leading to the 
formation of Schiff's bases. These complex series of 
reactions lead to browning and discoloration of the dosage 
form. Despite being a carrier of choice for dry powder 
aerosol formulations, lactose may need to be replaced with 
a different carrier, such as mannitol or sucrose, when 
formulating primary and secondary amines (eg, 
tobramycin). 
Formulating Peptides/Proteins 
Progress in the development of peptides as useful drugs 
has been impeded in part by their rapid excretion, resulting 
in short circulating lifetimes. This generated considerable 
interest in improving the duration of action of drugs 
through conjugation with the water-soluble, biocompatible 
excipient, poly(ethylene glycol). Such conjugates have 
reduced enzymatic degradation rates and lengthened 
circulating lifetimes compared to the native compounds. 
Other novel lipophilic carbohydrate excipients, termed 
oligosaccharide ester derivatives (OEDs), have been used 
to modify pharmacokinetic profiles of drugs. This 
technology is quite flexible, offering the ability to 
formulate drug molecules with modified-release 
characteristics and improved bioavailability. Another 
technology from the same company makes use of select 
carbohydrate excipients, such as trehalose and sucrose to 
stabilize molecules in the dry state, thereby preventing 
their physical and chemical degradation at ambient 
temperatures and above. These patent-protected drug 
delivery technologies are suited to the delivery of 
macromolecules, such as proteins and peptides by the 
pulmonary, oral, and injectable routes. 1, 
REGULATORY REQUIREMENT 
Regulatory requirements are part of the process of drug 
discovery and drug development. Regulatory requirements 
describe what is necessary for a new drug to be approved 
for marketing in any particular country. In the US, it is the 
function of the Food and Drug Administration (FDA) to 
establish these regulatory requirements. The European 
Medicines Agency (EMEA) and Japanese Pharmaceuticals 
and Medical Devices Agency (PMDA) are also important 
regulatory authorities in drug development. These three 
agencies oversee the three largest markets for drug sales. 
Historically, the various regulatory authorities have had 
their own methods for obtaining regulatory approval, 
however the rising cost of meeting the demands of 
differing regulations led to the establishment of an 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) in an attempt to co-ordinate and 
synthesize international regulatory requirements. The first 
Conference was held in Brussels in 1991, followed by ICH 
2 in Orlando, Florida in 1993, and ICH 3 in Yokohama, 
Japan in 1995. The Fourth International Conference on 
Harmonisation, in July 1997, was once again in Brussels. 
These systems of new drug approvals are extremely 
rigorous and costly. On average, it will cost a 
pharmaceutical company $359 million to get one new 
medicine from the laboratory to the pharmacist's shelf, 
according to a February 1993 report by the Congressional 
Office of Technology Assessment. It takes 12 years on 
average for an experimental drugto travel from the 
laboratory to the medicine chest. Only five in 5,000 
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compounds that enter preclinical testing will actually 
progress into human clinical trials, and of these five, only 
one is likely to be approved by the regulatory authorities.3, 
4
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Figure 2: Factors to consider when choosing a novel excipient for solid dosage forms
1 
NOVEL EXCIPIENTS AS DIFFERENT 
POLYMERS 
Poly (amidoamide)dendrimers 
Such polymers containing one or more types of 
membrane-targeting antimicrobial agents immobilized on 
a substrate with activity in relevant biological 
environments, and methods of making and using thereof, 
are described herein. The antimicrobial agents retain their 
activity in the presence of blood proteins and/or in vivo 
due to improved molecular structures which allow for 
cooperative action of immobilized agents and hydrophilic 
chemistries which resist non-specific protein adsorption. 
Suitable molecular structures include branched structures, 
such as dendrimers and randomly branched polymers. 
The molecule structures may also include hydrophilic 
tethers which provide both flexibility and resistance to 
non-specific protein adsorption. The membrane targeting 
antimicrobial agent coatings can be applied to a variety of 
different types of substrates including medical implants 
such as vascular grafts, orthopedic devices, dialysis 
access grafts, and catheters; surgical tools, surgical 
garments; and bandages. The substrates can be composed 
of metallic materials, ceramics, polymers, fibers, inert 
materials such as silicon, and combinations thereof. The 
compositions described herein are substantially non-
leaching, resistant to non-specific protein adsorption, and 
non-hemolytic.5, 6, 7 
Poly (L-lactide)-poly (oxyethylene)-poly (L-lactide) 
Such block copolymers obtained in bulk, by a ring 
opening mechanism, from poly (ethylene glycol)s (PEG)s 
and L-lactide (LA), at 120–140°C, in the absence of 
added catalysts are described. By using PEGs with 
different molecular masses, 3000 and 35000, respectively, 
and varying the initial molar ratio LA to PEG, two series 
of copolymers with different molecular masses, relative 
length of blocks and hydrophilicity were obtained.  
The morphological characteristics of the copolymers were 
investigated by means of X-ray diffractometry, optical 
and scanning electron microscopy. The biological 
properties of the materials were determined by evaluating 
their cytotoxicity, cytocompatibility, hemocompatibility 
and degradability using different standard tests. The 
results obtained indicate that the block copolymers 
synthesized may be useful for biomedical applications, in 
particular as restorable drug vehicles. The materials are 
brittle and their mechanical properties are not appropriate 
for implant devices.8, 9 
Poly(fumaric-co-sea-basic) 
Sea-basic acids are better candidates for bioadhesive 
delivery systems since, as hydrolysis proceeds, causing 
surface erosion, more and more carboxylic groups are 
exposed to the external surface. However, polylactides 
erode more slowly by bulk erosion. 
In designing bioadhesive polymeric systems based on 
polylactides, polymers that have high concentrations of 
carboxylic acid are preferred. This can be accomplished 
Physiochemical Properties of 
drug 
 Polymorphic 
forms/hydrates 
 Heat/moisture sensitive 
 Poorly soluble 
 Poorly absorbable 
 Poor stability in vivo 
 
Physiochemical properties 
of excipient 
 Physically stable? 
(polymorphic/forms 
hydrates) 
 Hygroscopic 
 Chemically stable 
 Compatible with drug 
 Rheology flow 
 
Manufacturing process 
requirement 
 Direct compression 
 Wet granulation 
 Fluid bed 
granulation/coating 
 Spray drying 
 Other novel processes 
 
Route of administration 
 Oral 
 Pulmonary 
 Transdermal 
 Buccal 
 Rectal/vaginal 
 
Delivered dose of drug 
 High dose 
 Low dose 
 
Desired release characteristics 
 Immediate release 
 Sustained release 
 Modified release              
e.g., enteric 
 
Excipient Choice in 
Solid Dosage Forms 
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by using low molecular weight polymers (Mw 2000), 
since low molecular weight polymers contain high 
concentration of carboxylic acids at the end groups. 
Measurement of Bioadhesive Properties using a tensile 
technique. 
Hydrogel microspheres were prepared by dripping a 
polymer solution from a reservoir though microdroplet 
forming device into a stirred ionic bath. The specific 
conditions for alginate, chitosan, 
alginate/polyethylenimide (PEI) and carboxymethyl 
cellulose (CMC) 
Polyacrylamide microspheres were produced by 
polymerizing an aqueous emulsion of acrylamide and 
bismethacrylamide in hexane.. This working solution was 
extensively degassed under water vacuum to remove 
dissolved oxygen which might inhibit the polymerization 
reaction.  
It requires Gene transfer in humans as carriers for the 
plasmid DNA which can efficiently and safely carry the 
gene into the nucleus of the desired cells. A series of 
chemically different cationic polymers are currently being 
investigated for these purposes. Although many cationic 
polymers indeed condense DNA spontaneously, which is 
a requirement for gene transfer in most types of cells, the 
physicochemical and biopharmaceutical behavior of the 
current generation of polyp lexes severely limits an 
efficient gene transfer in vitro and especially in vivo. 
This summarizes recent physicochemical and biological 
information on polyp lexes and aims to provide new 
insights with respect to this type of gene delivery system. 
Firstly, the chemical structure of frequently studied 
cationic polymers is represented. Secondly, the 
parameters influencing condensation of DNA by cationic 
polymers are described. Thirdly, the surface properties, 
solubility, aggregation behavior, degradation and 
dissociation of polyplexes are considered. The review 
ends by describing the in vitro and in 
vivogenetransfection behavior of polyplexes.10, 11, 12 
The Steryl (polylysine) 
It requires Gene transfer in humans as carriers for the 
plasmid DNA which can efficiently and safely carry the 
gene into the nucleus of the desired cells. A series of 
chemically different cationic polymers are currently being 
investigated for these purposes. Although many cationic 
polymersindeed condense DNAspontaneously, which is a 
requirement for gene transfer in most types of cells, the 
physicochemical and biopharmaceutical behavior of the 
current generation of polyp lexes severely limits an 
efficient gene transfer in vitro and especially in vivo. 
 This summarizes recent physicochemical and biological 
information on polyp lexes and aims to provide new 
insights with respect to this type of gene delivery system. 
Firstly, the chemical structure of frequently studied 
cationic polymers is represented. Secondly, the 
parameters influencing condensation of DNA by cationic 
polymers are described. Thirdly, the surface properties, 
solubility, aggregation behavior, degradation and 
dissociation ofpolyplexes are considered. The review 
ends by describing the in vitro and in 
vivogenetransfection behavior of polyp lexes. 
It relates to the delivery of desired compounds (e.g., 
nucleic acids) into cells using releasable delivery systems 
which include complexing nucleic acids and delivery 
ligands and used in the following applications as in Gene 
Therapy and Nucleic Acid, Polymers for Drug and 
Nucleic Acid Delivery, Condensation template 
polymerization of DNA, Endosome Diruption and Gene 
Expression.13, 14 
Polyaspartic acid (PASP), (A metal corrosion inhibitor), 
biodegradable and environment friendly, is a kind of 
green chemicals of demand increasing globally. The 
synthesis and application of PASP is popular in many 
countries because the problem of environment has been 
paid more and more attention. The field of PASP 
application is not same with different molecular weight 
range. 
Properties:  
PASP can be used as scale and corrosion inhibitor in 
industrial circulating cool water system, boiler water, 
reverse osmosis, oilfield water and desalination plant. The 
effects will be even better than ordinary 
organophosphines. When used in situation of high 
hardness, high alkaline, high pH value and high 
concentration index. When built with PBTCA, the 
synergism is obvious.  
 As a metal corrosion inhibitor, PASP has good corrosion 
inhibition ability with pH>10 and it also has good 
corrosion inhibition ability with low concentration for sea 
water. When built with organ phosphor, sodium tungstate, 
quatenary ammonium salt, zinc salt, molybdate, oxidized 
starch, and so on, the synergism is obvious. 
 As a nutrient absorption enhancer, PASP can be used in 
agriculture. When PASP is applied to fertilizer, it can 
enhance the availability of N, P, and K resulting in 
increased yields because of its high capacity for chelating 
metal ions.  
 As a new polymer, PASP can be reacted with cross 
linker into superabsorbent agent. This product with 
properties of non-pollution and fully biodegradation can 
be used for hygiene products. 15, 16 
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SUMMARY TABLE-1 
SR 
NO. 
COMPOUND NAME POLYAMIDO POLYETHER POLYETHYLENE 
POLYHISTIDYL GLYCOL 
1. Non-Proprietary Name: Amido polyether Glycolic acid 
2. Formula: C3H9SiO[C2H6SiO]400 [C29H59O3N2]8 SiC3H9 C2H4O3 
3. CAS No.: None 79-74-1 
4. Mol Weight: 34400 g/mole 76.05 g/mol 
 
5. 
 
Chemical Name: 
Siloxanes and silicones, Dimethyl, methyl 3-
[(2-lauroxy polyethyleneglycol Acetamido 
ethyl) amino] propyl, trimethylendblocked 
 
2-hdroxyethanoic acid 
 
6. 
Synonyms: Amido polyether modified silicone fluid, APM 
fluid, BY16-878 
Hydroxyacetic acid 
7. Description: Amine odor, with pale yellow, colored liquid 70% soluble in water 
Crystalline white powder 
OdorlessHygroscopic 
8. Structure: 
 
 
 
9. Related Compounds: Organic amines and 
HOOCCH2(C2H4O)4.5C12H25 
Lactic acid, glycerol, acetic acid 
10. Pharmaceutical 
Application: 
 Surface active agents keratolytic agent                                 
Acne treating agent 
11. Function Category: Fabric softner Used in skin treatments 
12. Storage: Store in cool and dry container Store at cool temperature 
13. Stability: React with strong acids It is quite stable 
14. Safety: Not explosive Strong irritant 
15. Handling Precaution: Skin irritant  Avoid breathing dust 
 Avoid eyes contact 
 
SUMMARY TABLE -2 
S N COMPOUND NAME STERYL POLY-LACTIDE STERYL POLY LYSINE 
1. Non-Proprietry Name: Polyester L-lysine monohydrochloride 
2. Formula: (C4H4O4)Y C6H15BrN2O2C6H15BrN2O2 
3. CAS No.: 33135-50-4 657-27-2 
4. Mol Weight: Measured by the DSC 182.62 g/mole 
5. Chemical Name: 4-dioxane-2,5-dione L-Lysine Monohydrochloride 
6. Synonyms: Polylactide, polylactic acid, PLA; 
Polyglycolide, Polyglycolic acid, PGA; 
2,6-Diaminohexanoic acid  
hydrochloride;L-Lysine Hydrochloride;  
Lyamine;Lysine Hydrochloride. 
7. Description: React slowly with water 
Forms in solid pallets or powder 
Off white colored, granular or powdered 
solid 
 
8. 
 
Structure: 
  
9. Related Compounds: Polylactide, polyglycoside L-Lysine, N2-L-histidyl 
10. Pharmaceutical 
Application: 
Used mainly in vaccine preparations. Bio reagent suitable for cell cultures. 
Charge enhancer for coating cell surface. 
11. Function Category: A polymer A polymer 
12. Storage: Store at cool temperature Store at cool temperature 
13. Stability: Less stable  
14. Safety: Material burnt if exposed to heat source Hazardous to skin and eye contact 
15. Handling Precaution:  Avoid eye contact 
 Avoid breathing dust 
May be toxic at high temperature 
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CONCLUSION: 
In short it can be said that challenges in formulation and 
drug delivery of active ingredients are impossible to solve 
with old excipients. Therefore, more research will be 
focused on development of novel excipients for efficient 
drug delivery at targeted site. Individual approval of 
excipient by separate registration process from finished 
product registration will provide guide to pharma 
companies for effective use of novel excipient in safe 
dosage. Due to this, research on novel excipient will also 
foster leading to their use in different dosage forms and 
routes. All these activities will promote innovation in 
novel excipients by providing ease of market approach and 
penetration to excipient companies. Final outcome of this 
will be effective, safe and reliable medicine to patient 
leading to betterment of mankind.  
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